Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Ianalumab add-on therapy in CLL patients receiving ibrutinib
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.
DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.
What are the next steps for CAR-T in myeloma?
Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future.
Magrolimab plus azacitidine in treatment-naïve AML
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.
First-in-human trial of an anti-BCMA ADC for R/R myeloma
Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.
Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes.
Immunotherapy Inches Forward in Development of Myeloid Malignancies
Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.
Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...
Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.
Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.